JP2013515748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515748A5 JP2013515748A5 JP2012546257A JP2012546257A JP2013515748A5 JP 2013515748 A5 JP2013515748 A5 JP 2013515748A5 JP 2012546257 A JP2012546257 A JP 2012546257A JP 2012546257 A JP2012546257 A JP 2012546257A JP 2013515748 A5 JP2013515748 A5 JP 2013515748A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- influenza
- particle
- envelope
- influenza antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims description 79
- 241000700605 Viruses Species 0.000 claims description 76
- 206010022000 influenza Diseases 0.000 claims description 54
- 238000002360 preparation method Methods 0.000 claims description 54
- 239000000427 antigen Substances 0.000 claims description 48
- 102000036639 antigens Human genes 0.000 claims description 48
- 108091007433 antigens Proteins 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 47
- 239000003381 stabilizer Substances 0.000 claims description 36
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 27
- 241000712461 unidentified influenza virus Species 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 19
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 13
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 13
- 239000000600 sorbitol Substances 0.000 claims description 13
- 230000000087 stabilizing effect Effects 0.000 claims description 13
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 10
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 7
- 125000000647 trehalose group Chemical group 0.000 claims description 7
- 241000714177 Murine leukemia virus Species 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 101710154606 Hemagglutinin Proteins 0.000 claims description 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 5
- 101710176177 Protein A56 Proteins 0.000 claims description 5
- 230000003139 buffering effect Effects 0.000 claims description 5
- 150000002016 disaccharides Chemical class 0.000 claims description 5
- 239000000185 hemagglutinin Substances 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 150000002772 monosaccharides Chemical class 0.000 claims description 5
- 239000000232 Lipid Bilayer Substances 0.000 claims description 4
- 238000004220 aggregation Methods 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 238000002983 circular dichroism Methods 0.000 claims description 4
- 230000036571 hydration Effects 0.000 claims description 4
- 238000006703 hydration reaction Methods 0.000 claims description 4
- JHDGGIDITFLRJY-UHFFFAOYSA-N laurdan Chemical compound C1=C(N(C)C)C=CC2=CC(C(=O)CCCCCCCCCCC)=CC=C21 JHDGGIDITFLRJY-UHFFFAOYSA-N 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 241001664176 Alpharetrovirus Species 0.000 claims description 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 3
- 241001231757 Betaretrovirus Species 0.000 claims description 3
- 241001663879 Deltaretrovirus Species 0.000 claims description 3
- 108010026586 Ebola virus nucleoprotein VP40 Proteins 0.000 claims description 3
- 241001663880 Gammaretrovirus Species 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 239000007987 MES buffer Substances 0.000 claims description 3
- 241001115401 Marburgvirus Species 0.000 claims description 3
- 102000005348 Neuraminidase Human genes 0.000 claims description 3
- 108010006232 Neuraminidase Proteins 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 239000007979 citrate buffer Substances 0.000 claims description 3
- 235000021474 generally recognized As safe (food) Nutrition 0.000 claims description 3
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 108700042481 virus VP40 Proteins 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 108010040721 Flagellin Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 125000000185 sucrose group Chemical group 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29043809P | 2009-12-28 | 2009-12-28 | |
| US61/290,438 | 2009-12-28 | ||
| PCT/US2010/062217 WO2011090712A2 (en) | 2009-12-28 | 2010-12-28 | Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016193457A Division JP2016222722A (ja) | 2009-12-28 | 2016-09-30 | インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013515748A JP2013515748A (ja) | 2013-05-09 |
| JP2013515748A5 true JP2013515748A5 (enExample) | 2014-01-09 |
| JP6073031B2 JP6073031B2 (ja) | 2017-02-01 |
Family
ID=44307476
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546257A Expired - Fee Related JP6073031B2 (ja) | 2009-12-28 | 2010-12-28 | インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法 |
| JP2016193457A Pending JP2016222722A (ja) | 2009-12-28 | 2016-09-30 | インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016193457A Pending JP2016222722A (ja) | 2009-12-28 | 2016-09-30 | インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20130028933A1 (enExample) |
| EP (1) | EP2519539A4 (enExample) |
| JP (2) | JP6073031B2 (enExample) |
| WO (1) | WO2011090712A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316356B (zh) * | 2012-03-22 | 2016-08-17 | 北京三诺佳邑生物技术有限责任公司 | 一种重组慢病毒载体制剂 |
| CN111729077A (zh) | 2013-03-14 | 2020-10-02 | 武田疫苗股份有限公司 | 减毒活甲病毒制剂的组合物和方法 |
| SG11201604136PA (en) * | 2013-12-19 | 2016-07-28 | Crucell Holland Bv | Improved formulations for virosomes |
| US10100093B2 (en) * | 2013-12-31 | 2018-10-16 | Epitopix Llc | Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use |
| CN107614008A (zh) * | 2015-03-20 | 2018-01-19 | 蓝鸟生物公司 | 载体制剂 |
| CA3005125A1 (en) | 2015-11-19 | 2017-05-26 | Novartis Ag | Buffers for stabilization of lentiviral preparations |
| ES2968923T3 (es) * | 2016-08-10 | 2024-05-14 | Celltrion Inc | Preparación farmacéutica líquida estable de anticuerpo contra el virus de la gripe |
| WO2019021957A1 (ja) * | 2017-07-25 | 2019-01-31 | 第一三共株式会社 | 点鼻用乾燥粉末医薬組成物 |
| KR20200090836A (ko) * | 2017-12-20 | 2020-07-29 | 조에티스 서비시즈 엘엘씨 | Hendra 및 Nipah 바이러스 감염을 대비한 백신 |
| US11523988B2 (en) * | 2018-11-29 | 2022-12-13 | Catalent U.K. Swindon Zydis Limited | Oral dispersible vaccine comprising virosomes |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| DE69520278T2 (de) * | 1995-11-25 | 2001-09-20 | Study Center Of Allergy Projects (S.C.A.P.), Haarlem | Verwendung eines Disaccharids als Stabilisator für flüssige Proteinmischungen sowie ein Disaccharid enthaltende flüssige Proteinmischungen |
| US6616931B1 (en) * | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| EP1294892B1 (en) * | 2000-06-23 | 2007-10-17 | Wyeth Holdings Corporation | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
| WO2002009674A2 (en) * | 2000-07-28 | 2002-02-07 | Inhale Therapeutic Systems, Inc. | Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds |
| US20100221284A1 (en) * | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
| WO2004042001A2 (en) * | 2002-05-17 | 2004-05-21 | Emory University | Virus-like particles, methods of preparation, and immonogenic compositions |
| KR20100107083A (ko) * | 2002-12-17 | 2010-10-04 | 메디뮨 엘엘씨 | 생물활성 물질의 고압 분무 건조 |
| NZ543467A (en) * | 2003-04-10 | 2008-07-31 | Novartis Vaccines & Diagnostic | The severe acute respiratory syndrome coronavirus |
| GB0313916D0 (en) * | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| BRPI0509493A (pt) * | 2004-04-01 | 2007-09-11 | Alza Corp | aparelho e método para a liberação transdérmica de vacina da influenza |
| CA2595380A1 (en) * | 2005-01-28 | 2006-08-03 | Wyeth | Stabilized liquid polypeptide formulations |
| WO2007044610A2 (en) * | 2005-10-07 | 2007-04-19 | Avatar Vaccines, Inc. | Virus-like particles and methods of use |
| EP1878791A1 (en) * | 2006-07-11 | 2008-01-16 | Bia Separations D.O.O. | Method for influenza virus purification |
| SG173997A1 (en) * | 2006-07-21 | 2011-09-29 | Univ California | Human endogenous retrovirus polypeptide compositions and methods of use thereof |
| WO2008094197A2 (en) * | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| US20080233150A1 (en) * | 2006-11-16 | 2008-09-25 | Gale Smith | Respiratory syncytial virus-virus like particle (vlps) |
| US20110177121A1 (en) * | 2008-02-21 | 2011-07-21 | Biological Mimetics, Inc. | Immunogenic Influenza Composition |
| CA2716546A1 (en) * | 2008-02-25 | 2009-09-03 | Novavax, Inc. | Sugar glassified virus like particles (vlps) |
| KR20120131725A (ko) * | 2011-05-26 | 2012-12-05 | 건국대학교 산학협력단 | 고병원성 조류인플루엔자 ａ ｈ５ｎ１ 바이러스 유사입자 및 이를 이용한 가금용 백신 |
| EP3305806B1 (en) * | 2012-02-13 | 2020-08-26 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
-
2010
- 2010-12-28 US US13/517,240 patent/US20130028933A1/en not_active Abandoned
- 2010-12-28 EP EP10844259.1A patent/EP2519539A4/en not_active Withdrawn
- 2010-12-28 WO PCT/US2010/062217 patent/WO2011090712A2/en not_active Ceased
- 2010-12-28 JP JP2012546257A patent/JP6073031B2/ja not_active Expired - Fee Related
-
2014
- 2014-03-06 US US14/199,887 patent/US20140186396A1/en not_active Abandoned
-
2016
- 2016-09-30 JP JP2016193457A patent/JP2016222722A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013515748A5 (enExample) | ||
| Wang et al. | Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases | |
| US20230390381A1 (en) | Immunogenic combinations | |
| Kerstetter et al. | Adenoviral vectors as vaccines for emerging avian influenza viruses | |
| US12440550B2 (en) | Immunogenic compositions and uses thereof | |
| JP2014503206A5 (enExample) | ||
| JP2023081859A (ja) | コロナウイルスワクチン | |
| JP2020528911A5 (enExample) | ||
| Quan et al. | Progress in the development of virus-like particle vaccines against respiratory viruses | |
| CN107106673A (zh) | 用于增强免疫应答的方法和组合物 | |
| Simnani et al. | COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review | |
| CN105473603B (zh) | 用于登革病毒疫苗的方法与组合物 | |
| Wang et al. | Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines | |
| Fang et al. | Development of mRNA rabies vaccines | |
| TW202430206A (zh) | 組合疫苗 | |
| Wong et al. | Influenza vaccination: options and issues | |
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| CN116650633A (zh) | 冠状病毒疫苗 | |
| JP2024523329A (ja) | ウイルス性疾患用の温度制御可能な自己複製ｒｎａワクチン | |
| CN114302737A (zh) | 制造三价线状病毒疫苗的组合物和方法 | |
| Gattinger et al. | Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O) | |
| Rao et al. | A single-dose mRNA vaccine protects mice from lethal Crimean-Congo hemorrhagic fever virus infection | |
| Lundstrom | COVID-19 Vaccines: Where Do We Stand at the End of 2023? | |
| HK40060960A (en) | Immunogenic combinations | |
| Ashraf et al. | COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines 2021, 9, 171 |